Clonal Analysis of the Quasispecies of Antiviral-Resistant HBV Genomes in Patients with Entecavir Resistance during Rescue Treatment and Successful Treatment of Entecavir Resistance with Tenofovir
Free accessResearch articleFirst published online January, 2013
Clonal Analysis of the Quasispecies of Antiviral-Resistant HBV Genomes in Patients with Entecavir Resistance during Rescue Treatment and Successful Treatment of Entecavir Resistance with Tenofovir
Clonal analysis of quasispecies of resistant HBV genomes in patients with entecavir (ETV) resistance receiving lamivudine (3TC) plus adefovir (ADV) rescue therapy has never been performed.
Methods
A sample of 10 patients with ETV resistance who were switched to 3TC+ADV treatment were analysed for changes in viral quasispecies. Serum samples at baseline, and at months 3 and 6 of 3TC+ADV treatment could be clonally analysed in 7 of 10 patients; 3–82 clones per sample (total 1,068 clones, mean 63) were sequenced.
Results
3TC+ADV therapy led to a modest decline in HBV DNA. Almost all clones had L180M and M204V 3TC resistance mutations before and during combination therapy. All clones had ≥1 of the S202G, T184F, T184A, T184L, T184I and M250V ETV resistance mutations. The percentages of detected clones bearing 3TC (rtL180M and rtM204V) and ETV mutations did not change with rescue 3TC+ADV therapy. In 7 of 8 patients with detectable HBV DNA (median 5.17 log10 copies/ml) after a median 24 months of ADV therapy, HBV DNA became undetectable with 3TC plus tenofovir after 6 months of treatment.
Conclusions
In patients with ETV resistance tenofovir is effective. Clonal analysis data indicate no selection of specific HBV mutants during rescue 3TC+ADV.
References
1.
EASL Clinical Practice Guidelines.Management of chronic hepatitis. J Hepatol2009; 50: 227–242.
2.
LokA.S.F., McMahonB.J.AASLD practice guidelines: chronic hepatitis B. Hepatology2007; 45: 507–539.
3.
YurdaydinC., AkarcaU.S.Treatment of chronic hepatitis B with telbivudine: wise hepatologists needed in hepatitis B endemic countries where treatment options are limited. Liver Int2011; 31: 589–591.
4.
LeungN.W., LaiC.L., ChangT.T.Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology2001; 33: 1527–1532.
5.
LocarniniS., HatzakisA., HeathcoteJ.Management of antiviral resistance in patients with chronic hepatitis B. Antivir Ther2004; 9: 679–693.
6.
YurdaydinC.Entecavir: a step forward in combating hepatitis B disease. Expert Opin Pharmacother2008; 9: 3095–3109.
7.
TenneyD.J., RoseR.E., BaldickC.J.Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology2009; 49: 1503–1514.
8.
HosakaT., SuzukiF., SuzukiY.Adefovir dipivoxil for treatment of breakthrough hepatitis caused by lamivudine-resistant mutants of hepatitis B virus. Intervirology2004; 47: 362–369.
9.
KaratayliE., KarayalçinS., KaraaslanH.A novel mutation pattern emerging during lamivudine treatment shows cross-resistance to adefovir dipivoxil treatment. Antivir Ther2007; 12: 761–768.
10.
SantantonioT., FasanoM., DurantelS.Adefovir dipivoxil resistance patterns in patients with lamivudine-resistant chronic hepatitis B. Antivir Ther2009; 14: 557–565.
11.
YimH.J., HussainM., LiuY., WongS.N., FungS.K., LokA.S.Evolution of multi-drug resistant hepatitis B virus during sequential therapy. Hepatology2006; 44: 703–712.
12.
IdilmanR., KaymakogluS., OnderF.O.A short course of add-on adefovir dipivoxil treatment in lamivudine-resistant chronic hepatitis B patients. J Viral Hepat2009; 16: 279–285.
13.
TenneyD.J., RoseR.E., BaldickC.J.Two-year assessment of entecavir resistance in lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present. Antimicrob Agents Chemother2007; 51: 902–911.
14.
ReijndersJ.G., DeterdingK., PetersenJ.Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues. J Hepatol2010; 52: 493–500.
15.
ShermanM., YurdaydinC., SollanoJ.Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology2006; 130: 2039–2049.
16.
ShermanM., YurdaydinC., SimsekH.Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks. Hepatology2008; 48: 99–108.
17.
BozdayıA.M., AslanN., BozdayiG.Molecular epidemiology of hepatitis B, C and D viruses in Turkish patients. Arch Virol2004; 149: 2115–2129.
18.
GüntherS., LiB.C., MiskaS.A novel method for efficient amplification of whole hepatitis B virus genomes permits rapid functional analysis and reveals deletion mutants in immunosuppressed patients. J Virol1995; 69: 5437–5444.
19.
YangH., WestlandC., XiongS., DelaneyW.E.4thIn vitro antiviral susceptibility of full-length clinical hepatitis b virus isolates cloned with a novel expression vector. Antiviral Res2004; 61: 27–36.
20.
BozkayaH., YurdaydinC., IdilmanR.Lamivudine treatment in HBeAg-negative chronic hepatitis B patients with low level viraemia. Antivir Ther2005; 10: 319–325.
21.
YatsujiH., HiragaN., MoriN.Successful treatment of an entecavir-resistant hepatitis B virus variant. J Med Virol2007; 79: 1811–1817.
22.
VilletS., OlliverA., PichoudC.Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient. J Hepatol2007; 46: 531–538.
23.
TenneyD.J.Genotypic determinants and phenotypic properties of antiviral-resistant HBV variants: insight from entecavir resistance studies. Antivir Ther2010; 15: 529–535.
24.
WarnerN., LocarniniS.The antiviral drug selected hepatitis B virus rtA181T/sW172* mutant has a dominant negative secretion defect and alters the typical profile of viral rebound. Hepatology2008; 48: 88–98.
25.
PanC.Q., HuK.Q., YuA.S.Response to tenofovir monotherapy in chronic hepatitis B patients with prior suboptimal response to entecavir. J Viral Hepat2012; 19: 213–219.
